Merck KGaA 1. Mai 2026 Merck KGaA Backs Hybrid Cancer Drugs And Greener Lab Consumables - simplywall.st
Merck KGaA 1. Mai 2026 Merck KGaA doses first patient in Phase III programme of enpatoran - Clinical Trials Arena
Merck KGaA 28. Apr. 2026 Remepy, Merck KGaA pair up to test app-paired drug model in rare tumour - FirstWord Pharma
Merck KGaA 28. Apr. 2026 Merck KGaA and Remepy join forces to develop combo drug-digital therapies - Medical Device Network
Merck KGaA 27. Apr. 2026 Merck KGaA: Small Breakout In 2026, Followed By Normalization (OTCMKTS:MKGAF) - Seeking Alpha
FierceBiotech 22. Apr. 2026 Merck goes with Google for AI push, striking enterprise partnership worth up to $1B
FierceBiotech 21. Apr. 2026 In a Merck Litespark shocker, Welireg triplet misses the mark in first-line kidney cancer
BioPharma Dive 20. Apr. 2026 AACR 2026: Revolution’s next prospect, Merck’s reveal and a lung cancer battle
FierceBiotech 17. Apr. 2026 Merck unveils PD-1xVEGF bispecific data in NSCLC, remains tight-lipped on phase 3 plans
Endpoints News 8. Apr. 2026 Merck adjusts its vaccine supply deal in China; Soleno withdraws EU application
Endpoints News 7. Apr. 2026 Terns sold to Merck for 13% lower than pharma's initial offer because of clinical data